{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:07:40Z","timestamp":1789567660012,"version":"build-2803163510"},"reference-count":42,"publisher":"American Chemical Society (ACS)","issue":"36","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Macrocyclic peptides are attracting attention as a promising therapeutic modality for addressing intracellular targets that are traditionally difficult to address with conventional small molecules or antibodies. In this study, we present the chemical optimization process behind the development of AUBE00 (AP7400, compound 30), a KRAS-selective inhibitor based on a scaffold similar to LUNA18, an orally bioavailable macrocyclic peptide RAS inhibitor. Achieving KRAS isoform selectivity is exceptionally challenging due to the nearly identical backbone structures of KRAS, HRAS, and NRAS (C\u03b1 RMSD &amp;lt; 1.1 \u00c5). The success of this study relied on two critical factors: (1) achieving conformational control of the flexible N-alkyl group through a bridging structure linked to the adjacent side chain, which enabled the exploitation of subtle interaction energy differences among the isoforms; and (2) overcoming the trade-off between improved KRAS selectivity and reduced permeability associated with P-glycoprotein (P-gp) substrate liability by employing a modified Caco-2 membrane permeability assay to recover oral bioavailability. Our results demonstrate that a conformational rigidification through a bridged scaffold, implemented while preserving membrane permeability, is a highly effective strategy for achieving isoform selectivity. This study establishes a generalizable design principle for orally bioavailable macrocyclic peptides targeting intracellular proteins that require mutation or isoform selectivity.<\/jats:p>","DOI":"10.1021\/jacs.6c14212","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:24:39Z","timestamp":1788495879000},"page":"39227-39239","source":"Crossref","is-referenced-by-count":0,"title":["Exploiting Bridged\nConformations for Precise Molecular\nRecognition in the Design of KRAS-Selective, Orally Available Macrocyclic\nPeptides"],"prefix":"10.1021","volume":"148","author":[{"given":"Mirai","family":"Kage","sequence":"first","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsuo","family":"Kawada","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-0908","authenticated-orcid":true,"given":"Atsushi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Murata","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kotake","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shino","family":"Kuramoto","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamano","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Irie","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Ohara","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuji","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-9502","authenticated-orcid":true,"given":"Kenichi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Morita","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Wakamiya","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Takei","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-3339","authenticated-orcid":true,"given":"Yoshikazu","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Iikura","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5474-9274","authenticated-orcid":true,"given":"Mikimasa","family":"Tanada","sequence":"additional","affiliation":[{"name":"Chugai Pharmaceutical Co., Ltd. , , , ,","place":["Yokohama, Kanagawa, Japan, 244-8602"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"48","key":"2026091609124431400_cit1","doi-asserted-by":"publisher","first-page":"21571","DOI":"10.1002\/anie.202004550","article-title":"Drug-Like Properties in Macrocycles above MW 1000:\nBackbone Rigidity versus Side-Chain Lipophilicity","volume":"59","author":"Furukawa","year":"2020","journal-title":"Angew. Chem., Int. Ed."},{"issue":"10","key":"2026091609124431400_cit2","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1016\/j.bmc.2017.08.031","article-title":"Improving oral bioavailability\nof cyclic peptides by N-methylation","volume":"26","author":"Ra\u0308der","year":"2018","journal-title":"Bioorg.\nMed. Chem."},{"issue":"19","key":"2026091609124431400_cit3","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1016\/j.cell.2022.07.019","article-title":"Accurate de novo design\nof membrane-traversing macrocycles","volume":"185","author":"Bhardwaj","year":"2022","journal-title":"Cell"},{"issue":"7172","key":"2026091609124431400_cit4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/nature06526","article-title":"Reaching\nfor high-hanging fruit in drug discovery at\nprotein-protein interfaces","volume":"450","author":"Wells","year":"2007","journal-title":"Nature"},{"key":"2026091609124431400_cit5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cbpa.2017.03.011","article-title":"Targeting intracellular protein-protein\ninteractions with cell-permeable cyclic peptides","volume":"38","author":"Qian","year":"2017","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"6","key":"2026091609124431400_cit6","doi-asserted-by":"publisher","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin. A review\nof its pharmacodynamic\nand pharmacokinetic properties, and therapeutic use in immunoregulatory\ndisorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"issue":"18","key":"2026091609124431400_cit7","doi-asserted-by":"publisher","first-page":"13131","DOI":"10.1021\/acs.jmedchem.1c00580","article-title":"Cyclosporin\nStructure and Permeability: From A to Z and Beyond","volume":"64","author":"Corbett","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026091609124431400_cit8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molstruc.2012.11.005","article-title":"Spatial\nstructure of cyclosporin A and insight into its flexibility","volume":"1036","author":"Efimov","year":"2013","journal-title":"J. Mol. Struct."},{"issue":"44","key":"2026091609124431400_cit9","doi-asserted-by":"publisher","first-page":"24035","DOI":"10.1021\/jacs.3c07145","article-title":"Validation of a New Methodology to Create Oral Drugs\nbeyond the Rule of 5 for Intracellular Tough Targets","volume":"145","author":"Ohta","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"23","key":"2026091609124431400_cit10","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.1073\/pnas.94.23.12297","article-title":"RNA-peptide fusions\nfor the in vitro selection of peptides\nand proteins","volume":"94","author":"Roberts","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"2","key":"2026091609124431400_cit11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/s0014-5793(97)01026-0","article-title":"In Vitro virus: bonding\nof mRNA bearing puromycin at the 3\u2032-terminal end to the C-terminal\nend of its encoded protein on the ribosome in vitro","volume":"414","author":"Nemoto","year":"1997","journal-title":"FEBS Lett."},{"issue":"11","key":"2026091609124431400_cit12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.chembiol.2003.11.004","article-title":"Encodamers: unnatural\npeptide oligomers\nencoded in RNA","volume":"10","author":"Frankel","year":"2003","journal-title":"Chem. Biol."},{"issue":"33","key":"2026091609124431400_cit13","doi-asserted-by":"publisher","first-page":"11727","DOI":"10.1021\/ja0515809","article-title":"Ribosomal\nsynthesis of unnatural\npeptides","volume":"127","author":"Josephson","year":"2005","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"2026091609124431400_cit14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth877","article-title":"A highly flexible tRNA\nacylation method for non-natural polypeptide synthesis","volume":"3","author":"Murakami","year":"2006","journal-title":"Nat. Methods"},{"issue":"22","key":"2026091609124431400_cit15","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acs.jmedchem.1c01599","article-title":"A Series of Novel, Highly Potent, and Orally Bioavailable\nNext-Generation Tricyclic Peptide PCSK9 Inhibitors","volume":"64","author":"Tucker","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"2026091609124431400_cit16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally\nBioavailable Macrocyclic Peptide That Inhibits\nBinding of PCSK9 to the Low Density Lipoprotein Receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"issue":"8","key":"2026091609124431400_cit17","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies:\nis the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug\nDiscovery"},{"issue":"11","key":"2026091609124431400_cit18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd.2016.139","article-title":"Direct small-molecule inhibitors\nof KRAS: from structural\ninsights to mechanism-based design","volume":"15","author":"Ostrem","year":"2016","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"2","key":"2026091609124431400_cit19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib\nin Non-Small-Cell Lung Cancer Harboring a\nKRAS(G12C) Mutation","volume":"387","author":"Ja\u0308nne","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"2026091609124431400_cit20","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the Clinical Development\nCandidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment\nof Cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"7781","key":"2026091609124431400_cit21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical\nKRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026091609124431400_cit22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery\nof a Covalent\nInhibitor of KRAS(G12C) (AMG 510) for the Treatment of Solid Tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"30","key":"2026091609124431400_cit23","doi-asserted-by":"publisher","first-page":"16610","DOI":"10.1021\/jacs.3c03886","article-title":"Development\nof Orally Bioavailable Peptides Targeting an Intracellular\nProtein: From a Hit to a Clinical KRAS Inhibitor","volume":"145","author":"Tanada","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"2026091609124431400_cit24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117830","article-title":"Structure-activity\nrelationships of middle-size cyclic\npeptides, KRAS inhibitors derived from an mRNA display","volume":"110","author":"Kage","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"2026091609124431400_cit25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins\nand Their Regulators\nin Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"1","key":"2026091609124431400_cit26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.cr.7290105","article-title":"MAPK signal pathways\nin the regulation of cell proliferation\nin mammalian cells","volume":"12","author":"Zhang","year":"2002","journal-title":"Cell Res."},{"issue":"4","key":"2026091609124431400_cit27","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1535-6108(03)00248-4","article-title":"Targeting\nthe PI3K-Akt pathway in\nhuman cancer: rationale and promise","volume":"4","author":"Luo","year":"2003","journal-title":"Cancer\nCell"},{"issue":"18","key":"2026091609124431400_cit28","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa2505783","article-title":"Daraxonrasib in Previously Treated Advanced\nRAS-Mutated Pancreatic Cancer","volume":"394","author":"Wolpin","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"2026091609124431400_cit29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","article-title":"KRAS(G12C)-independent feedback activation of wild-type\nRAS constrains KRAS(G12C) inhibitor efficacy","volume":"39","author":"Ryan","year":"2022","journal-title":"Cell Rep."},{"issue":"7968","key":"2026091609124431400_cit30","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables\noncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"8","key":"2026091609124431400_cit31","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202414256","article-title":"Mirror-Image Random Nonstandard Peptides Integrated\nDiscovery (MI-RaPID) Technology Yields Highly Stable and Selective\nMacrocyclic Peptide Inhibitors for Matrix Metallopeptidase 7","volume":"64","author":"Ghareeb","year":"2025","journal-title":"Angew. Chem., Int. Ed."},{"issue":"3","key":"2026091609124431400_cit32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.chembiol.2017.02.001","article-title":"Rapid Discovery of\nPotent and Selective Glycosidase-Inhibiting De\nNovo Peptides","volume":"24","author":"Jongkees","year":"2017","journal-title":"Cell Chem. Biol."},{"issue":"8","key":"2026091609124431400_cit33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.str.2023.05.009","article-title":"Discovery\nand characterization of cyclic peptides selective for the C-terminal\nbromodomains of BET family proteins","volume":"31","author":"Franck","year":"2023","journal-title":"Structure"},{"issue":"23","key":"2026091609124431400_cit34","doi-asserted-by":"publisher","first-page":"4723","DOI":"10.1016\/j.jmb.2016.10.017","article-title":"Structural Dynamics\nin Ras and Related Proteins upon Nucleotide Switching","volume":"428","author":"Harrison","year":"2016","journal-title":"J. Mol. Biol."},{"issue":"3","key":"2026091609124431400_cit35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane\ntransporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat. Rev.\nDrug Discovery"},{"issue":"6","key":"2026091609124431400_cit36","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1873-3468.14018","article-title":"ABCB1\/MDR1\/P-gp employs an ATP-dependent\ntwist-and-squeeze mechanism to export hydrophobic drugs","volume":"595","author":"Kodan","year":"2021","journal-title":"FEBS Lett."},{"issue":"3","key":"2026091609124431400_cit37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1248\/bpb.b19-00641","article-title":"Estimating\nEfflux Transporter-Mediated Disposition of Molecules beyond the Rule\nof Five (bRo5) Using Transporter Gene Knockout Rats","volume":"43","author":"Miyake","year":"2020","journal-title":"Biol. Pharm. Bull."},{"issue":"6","key":"2026091609124431400_cit38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal\nfirst-pass metabolism of substrates\nof CYP3A4 and P-glycoprotein-quantitative analysis based on information\nfrom the literature","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"16","key":"2026091609124431400_cit39","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450\n3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res."},{"issue":"3","key":"2026091609124431400_cit40","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1124\/jpet.120.000158","article-title":"Calculation of an Apical Efflux Ratio from P-Glycoprotein (P-gp)\nIn Vitro Transport Experiments Shows an Improved Correlation with\nIn Vivo Cerebrospinal Fluid Measurements in Rats: Impact on P-gp Screening\nand Compound Optimization","volume":"376","author":"Fischer","year":"2021","journal-title":"J. Pharmacol. Exp.\nTher."},{"issue":"2","key":"2026091609124431400_cit41","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0022-3565(24)34974-2","article-title":"Selectivity of the multidrug resistance modulator,\nLY335979, for P-glycoprotein and effect on cytochrome P-450 activities","volume":"290","author":"Dantzig","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"2026091609124431400_cit42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ijc.10792","article-title":"Modulation of P-glycoprotein but\nnot MRP1- or BCRP-mediated drug resistance by LY335979","volume":"103","author":"Shepard","year":"2003","journal-title":"Int. J. Cancer"}],"container-title":["Journal of the American\nChemical Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/jacs.6c14212","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jacsat\/article-pdf\/148\/36\/39227\/68332810\/jacs.6c14212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jacsat\/article-pdf\/148\/36\/39227\/68332810\/jacs.6c14212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:04Z","timestamp":1789565464000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jacsat\/article\/148\/36\/39227\/5416596\/Exploiting-Bridged-Conformations-for-Precise"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":42,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2026,9,3]]},"published-print":{"date-parts":[[2026,9,16]]}},"URL":"https:\/\/doi.org\/10.1021\/jacs.6c14212","relation":{},"ISSN":["0002-7863","1520-5126"],"issn-type":[{"value":"0002-7863","type":"print"},{"value":"1520-5126","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}